The novel coronavirus (COVID-19) pandemic and accompanying disease-mitigation measures have had an unprecedented global impact. As of the time of writing, the WHO identifies over 10.1 million global cases (2.5 million US) and more than 500,000 fatalities (126,000 US) (World Health Organization [@CR21], [@CR22]; Centers for Disease Control [@CR2]).

The WHO defines disability as "any condition of the body or mind that makes it more difficult for the person with the condition to do certain activities and interact with the world around them" (World Health Organization [@CR21], [@CR22]). Even prior to the COVID-19 pandemic, persons with disabilities (PWD) were at greater risk for difficulties accessing healthcare, performing instrumental activities of daily living, and maintaining financial well-being (Kweon [@CR10]; Lenze et al. [@CR11]; Garberoglio et al. [@CR3]; Gopinath et al. [@CR5]; World Health Organization [@CR19], [@CR20]). The impact of the COVID-19 on PWD has not been well described, and it is not known whether the pandemic is disproportionally creating challenges for PWD. Mitigation measures currently in place across the globe are likely to exacerbate many psychological, financial, and day-to-day challenges (Gershman [@CR4]).

Recently, scientific publications and advocacy groups have provided broad recommendations to limit the impact of the pandemic on PWD (Allen and Smith [@CR1]; Senjam [@CR15]; Kessler Foundation [@CR8]; National Association of the Deaf [@CR12]; Rogers [@CR14]). However, there are little data to quantify the impact of the pandemic on PWD, and a thorough review of existing survey instruments demonstrated a clear gap in available instruments to assess the impact on PWD. While long-standing rigorously validated survey instruments like the WHO Model Disability Survey are commonly used in disability survey research, existing instruments may lack content validity since they were not developed with this unprecedented global stressor in mind (World Health Organization [@CR21], [@CR22]). We also reviewed all COVID-19 surveys cataloged on the PhenX Toolkit website (Hamilton et al. [@CR6]); however, there was no single instrument that appeared well targeted to PWD. Accordingly, the decision was made to undertake the development of a novel survey instrument to conduct research specific to the impact of COVID-19 on PWD. Given the highly specific nature of this construct, we believe that this new instrument was needed in order to optimize key measurement properties like content and construct validity (Terwee et al. [@CR16]).

We therefore developed a novel survey instrument, the Coronavirus Disability Survey (COV-DIS), for the purpose of assessing the impact of the COVID-19 pandemic and related disease-mitigation measures on PWD. The survey includes items to assess general and psychological health, instrumental activities of daily living, social isolation, financial strain, and information and transportation access.

The 34-item COV-DIS was developed by consensus of a group of experts from the fields of survey research, physical medicine and rehabilitation, family medicine, ophthalmology, and industrial and operations engineering. All experts on the panel had extensive expertise in disability research and/or the clinical care of PWD. The panel drafted and iteratively refined relevant novel survey items. Additionally, based on the review of existing instruments, several items were drawn from other surveys. Items were included from the: CDC COVID-19 Community Survey, Osteoporotic Fractures in Men Study (MROS) and Study of Muscle Mobility and Aging (SOMMA) (Ware and Sherbourne [@CR18]), Understanding America Study (Orwoll et al. [@CR13]), 36-item Short-Form Survey (SF-36) (Hays et al. [@CR7]), and Patient Health Questionnaire-2 (PHQ-2) (Kroenke et al. [@CR9]). Responses to these items can therefore be easily harmonized with data from their parent studies in order to make comparisons between populations. For example, studies from which several of the COV-DIS items were drawn make data publicly available. Data may be directly compared between a study conducted with the COV-DIS and publicly available data (e.g., a national sample in the Understanding America Study). Items from validated instruments such as the SF-36 and the PHQ-2 can also be compared to data from national samples collected in large epidemiological studies (e.g., the Health and Retirement Study or the National Health and Aging Trends Study).

Various COV-DIS items allow for the input of free text to describe the unique experience of respondents. Questions ask respondents to compare current experiences to their experiences prior to becoming aware of the pandemic. This approach may be relevant to the current phase of the pandemic. However, the nature of the pandemic and mitigation measures is likely to change in unpredictable ways. Therefore, it is likely that there will be a need for future users of the COV-DIS to modify question stems in order to specify a timeframe of interest.

We are presently utilizing the COV-DIS to carry out research on the impact of COVID-19 on PWD in southeast Michigan, USA, an area strongly affected by the pandemic (The New York Times [@CR17]). Data will be analyzed to determine the psychometric properties of the COV-DIS and to obtain critical insights into how the COVID-19 pandemic and disease-mitigation measures are affecting the health and well-being of PWD in this region.

The COV-DIS represents a novel instrument to facilitate an urgent research need. However, there are several limitations. Since results of the initial administration of the COV-DIS are not yet available, the measurement properties of the survey are not known. Additionally, qualitative research was not performed among PWD in order to inform instrument development. Nonetheless, these limitations are due to what we believe was the need to rapidly develop and disseminate a highly relevant survey instrument to enable meaningful research that may benefit the lives of PWD during the COVID-19 pandemic.

In developing and making the COV-DIS freely and publicly available (<https://osf.io/p2w9j/.>), we hope to promote opportunities for harmonization of data across diverse study populations. Studies using the COV-DIS may have a large impact by providing needed insights to shape data-driven public health and policy decisions that have the potential to optimize the health and well-being of PWD now, during possible future waves of COVID-19 infection, and during other future high-impact societal stressors.
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